At GEA we believe that continuous processing improves the quality of pharmaceutical end products: by focusing on quality during the whole product life-cycle, not just “tested in” quality; and by understanding the capability of your processes, managing sources of variability and decreasing any associated risks.
Our solution for continuous tableting lines is ConsiGma®, a 6 sigma-inspired manufacturing platform, incorporating different technologies to produce oral solid dosage forms in a continuous, cost-efficient way:
Showing 4 of 6
The ConsiGma® CF20 test rig is a standalone module that allows you to characterize the feeding behavior of your products during the early stages of R&D.
An indispensable part of the ConsiGma 4.0 portfolio, the Conductor 4.0 control system architecture ensures smooth operation and communication between the different elements of a pharmaceutical continuous manufacturing line
A highly integrated solution for continuous linear blending and direct compression, the ConsiGma® DC-LB lines offer all the advantages of continuous manufacturing: supply chain agility, small footprint, controlled blending and compression and improved quality.
Designed to achieve optimal blending results, the ConsiGma® DB modules facilitate the testing of dosing and blending operations and can be integrated with any continuous up- or downstream process.
Every drop and every kilowatt hour count when it comes to centrifuge development.
GEA has been building centrifuges for over 130 years – something you wouldn’t think is in question every day. Jürgen Mackel, Vice President...
Through investments in renewable energy, GEA is lowering its CO2 emissions around the world.
When it comes to improving the health of the planet, GEA takes a leading role. As one of our sustainability-focused strategic objectives, we are forging a path to help our customers across myriad industries to reduce energy use...